💸 The Tape

The Canadian cannabis company has completed its acquisition of Sanity Group, one of Europe's leading pure-play cannabis companies, in a deal worth up to €221.1 million when including potential earnout payments. The transaction, backed by significant financial support from British American Tobacco (BAT), transforms Organigram from a primarily domestic Canadian operator into a company with a genuine multi-country European footprint — and signals that the next phase of cannabis industry consolidation may be playing out across the Atlantic.

The Deal Structure

The upfront purchase price came in at €107.3 million, split between €78 million in cash and €29.3 million in share consideration. Organigram issued 3,146,195 common shares to Sanity's former shareholders and 12,638,228 non-voting Class A convertible preferred shares to BAT, all priced at €1.8547 (C$3.00) per share.

Beyond the upfront payment, Sanity's former owners are eligible for earnout consideration of up to €113.8 million — comprised of up to €20 million in cash and up to €93.8 million in shares — contingent on Sanity Group's financial performance during the 12-month period ending April 1, 2027. The share component of the earnout is subject to a C$3.00 floor and C$4.00 cap based on Organigram's volume-weighted average trading price, providing some pricing certainty for both sides.

If Sanity hits its targets, the total deal value reaches roughly €221 million — a substantial bet on European cannabis by any measure.

How It's Being Funded

Organigram assembled a multi-layered financing stack to get this done. The cash portion of the upfront consideration was partially funded through the Jupiter Pool, a strategic investment capital reserve established in 2024 with funding from BAT specifically to support international growth initiatives. This acquisition represents the final deployment of that pool — meaning the money BAT earmarked for Organigram's global ambitions has now been fully put to work.

Concurrently, the company closed a private placement with BAT generating total gross proceeds of €40.3 million (C$65.2 million). BAT acquired a mix of common and preferred shares structured carefully to keep its ownership below the 30% voting threshold — a regulatory line that, if crossed, would trigger mandatory takeover bid requirements under Canadian securities law. Where the common share allocation would have pushed BAT past that threshold, the remainder was issued as non-voting convertible preferred shares.

Those preferred shares come with an interesting kicker: they convert into common shares on a one-for-one basis initially, but the conversion rate increases at 7.5% annually until BAT's potential ownership reaches 49% of outstanding common shares. It's a mechanism that gives BAT a gradually expanding economic interest without immediately triggering governance implications — a patient, structured approach to building a controlling position over time.

Rounding out the financing, Organigram secured senior secured credit facilities of up to C$60 million through ATB Financial, consisting of a C$20 million term loan (drawn at closing to help fund the acquisition), a C$30 million revolving credit facility (available for earnout obligations and working capital), and a C$10 million operating facility. The facilities mature in April 2029 and can be repaid without penalty at any time.

What Sanity Group Brings

Headquartered in Germany, Sanity Group has built a scalable European platform with operations spanning Switzerland, the United Kingdom, Poland, and Czechia. The company operates across multiple segments of the cannabis value chain — medical cannabis, regulated recreational pilot programs, and wellness products — with deep regulatory expertise, established distribution and logistics capabilities, and a broad network of strategic partners.

For Organigram, this isn't just a revenue acquisition. It's an infrastructure play. Europe's cannabis landscape is fragmented, heavily regulated, and evolving at different speeds across jurisdictions. Having a partner already embedded in multiple markets — with the regulatory relationships and distribution networks already built — is worth more than the financial metrics alone suggest.

Germany in particular has emerged as the continent's most significant cannabis market following its recreational legalization framework, and Sanity's positioning there gives Organigram a front-row seat to what could become the largest legal cannabis market in Europe.

The BAT Factor

No discussion of this deal is complete without acknowledging the elephant — or rather, the tobacco giant — in the room. British American Tobacco's involvement in Organigram has deepened significantly with this transaction. Between the Jupiter Pool funding, the private placement, and the preferred share structure with its escalating conversion rate, BAT is methodically building toward what could eventually become a near-majority ownership position in Organigram.

The strategic logic from BAT's perspective is transparent: the global tobacco industry is in structural decline, and cannabis represents one of the most credible adjacent growth categories available. Rather than building a cannabis operation from scratch, BAT is using Organigram as its vehicle — funding international expansion, providing patient capital, and structuring its ownership to grow over time without triggering immediate regulatory complications.

For Organigram, the relationship provides something most cannabis companies desperately lack: a deep-pocketed strategic partner willing to fund acquisitions of this scale without forcing the company into the kind of dilutive emergency financings that have plagued the sector.

Looking Ahead

With the Sanity acquisition closed and the Jupiter Pool fully deployed, Organigram enters its next chapter as a genuinely transatlantic cannabis operator. The appointment of Max Konrad Narr to Organigram's board — for the duration of the earnout period — ensures Sanity's leadership maintains influence over the integration.

The earnout structure means the next twelve months will be critical. If Sanity delivers on its performance targets, the total deal cost escalates significantly. If it doesn't, Organigram will have acquired a European platform at a relative discount. Either way, the company has positioned itself where few Canadian cannabis operators have managed to land: on the ground in Europe, with capital, infrastructure, and a partner with very deep pockets.

The map just got a lot bigger.

📈 Dog Walkers

$TLRY ( ▲ 0.58% ) UK Lyphe M&A + BrewDog Investment + Rescheduling Prep +$180M ATM

Tilray Brands is making it abundantly clear that it doesn't intend to be just a cannabis company — and this week's flurry of announcements reads like a strategic manifesto for what comes next.

The company unveiled a series of moves spanning medical cannabis, craft beverages, and U.S. market positioning, each designed to reinforce Tilray's identity as a diversified global consumer platform rather than a single-industry operator. It's ambitious. Whether it's overextended or perfectly timed depends on which bet you're watching.

Lyphe Acquisition: Building a Medical Ecosystem

Tilray has acquired the Lyphe Group, a leading UK-based medical cannabis clinic and digital pharmacy platform that has dispensed approximately 150,000 units and treated over 16,000 patients to date. The deal gives Tilray its first fully vertically integrated medical platform — combining pharmaceutical-grade cultivation and production with clinical care, dispensing services, and digital patient access under one roof.

The integration extends beyond cannabis. Tilray plans to leverage CC Pharma's established distribution scale and sourcing capabilities to supply traditional prescription medicines through the Lyphe platform, broadening the model into a comprehensive pharmaceutical distribution network across the UK.

International President Rajnish Ohri said the business is expected to be accretive by 2027 and represents a step toward building a "fully connected, international medical ecosystem." For Tilray, the Lyphe deal isn't just about cannabis patients — it's about establishing healthcare infrastructure that can flex across therapeutic categories and geographies.

BrewDog: Rebuilding Toward a Billion

Just six weeks after closing its acquisition of BrewDog, Tilray is already laying out an aggressive revitalization plan for the iconic craft beer brand. The company has stabilized brewing volumes, maintained service levels across channels, and begun onboarding new distribution partners to support expansion.

CEO Irwin Simon didn't mince words about the ambition: Tilray sees "a clear path to rebuilding BrewDog toward its prior valuation of over $1 billion." The plan involves expanding distribution across the UK, Australia, and the United States, while developing the brand in emerging markets including the Middle East and India.

Tilray is also investing in what it calls a "brewpub of the future" at an existing BrewDog location — a test concept designed to modernize the in-venue experience and inform future changes across the brewpub network. The company expects BrewDog to be cash flow positive by 2027.

Beyond BrewDog, Tilray is seeing growing demand for its American craft portfolio in the UK and plans to launch Hi*Ball Energy there in May, pushing further into the functional beverage space.

Eyes on U.S. Rescheduling

Stateside, Tilray is positioning itself for what it clearly believes is an inevitable shift: the rescheduling of cannabis under federal law. The company says it's actively engaged with legislators and regulators and is evaluating participation in a Center for Medicare and Medicaid Innovation pilot program that would partner with oncology practices and Accountable Care Organizations to supply hemp-derived medical cannabis to underserved patients.

Chief Strategy Officer Denise Faltischek expressed confidence that rescheduling will happen "in the near-term," pointing to Tilray Medical's track record across more than 20 regulated markets worldwide as proof of readiness.

The ATM Filing

To fund all of this, Tilray filed an at-the-market equity program of up to $180 million, managed by Jefferies, TD Securities, and Roth Capital Partners. It's a capital flexibility tool that allows the company to raise funds incrementally as opportunities arise — though investors will inevitably watch for dilution pressure on a stock that has already weathered its share of turbulence.

Tilray is building a company that spans clinics, brewpubs, dispensaries, and pharmacy platforms across multiple continents. The vision is sweeping. The execution will determine everything.

$ACB ( ▲ 4.25% ) Bolsters EU GMP Assets

The company has acquired Safari Flower Company, an EU GMP certified cannabis cultivator and manufacturer based in Ontario, for aggregate consideration valued at $26.5 million. The deal includes $15 million in cash and 2,417,180 common shares issued at closing, plus a contingent $2 million cash payment tied to certain conditions.

Safari brings a 59,000-square-foot purpose-built indoor facility with cultivation and manufacturing capabilities that align closely with Aurora's existing operations. The strategic play is straightforward: more EU GMP certified flower to feed growing demand in Germany, Australia, Poland, and the UK — markets where regulatory barriers are high, margins are attractive, and supply remains constrained.

CEO Miguel Martin framed the acquisition as a deliberate investment in the international medical cannabis market, noting that Aurora intends to apply its plant science and operational expertise to improve yields and drive efficiencies across the expanded supply network.

The transaction is expected to deliver positive adjusted EBITDA contributions in fiscal 2027, with further upside in fiscal 2028 and beyond as the facility is fully integrated.

For Aurora, the message is clear: the international medical game is a capacity race, and they're not standing still.

🗞️ The News

📺 YouTube

Who’s Ready for Post-280E Cannabis? | TTB Presented by Flowhub

What we will cover:

✅ In the latest Trade To Black podcast presented by Flowhub, hosts Shadd Dales and Anthony Varrell sit down with Terry Mendez, CEO of Safe Harbor Financial (NASDAQ: SHFS), to understand what happens next as cannabis moves closer to federal reform.

The focus here is simple—who’s actually ready for a post-280E world?

Because if cannabis is rescheduled to Schedule III, the removal of 280E would completely change the financial picture for operators. Lower tax burdens, stronger cash flow, and healthier balance sheets all sound great—but not every company is built to take advantage of that shift.

We break down the difference between operators that are already running like real businesses—with proper financials, compliance, and banking relationships—and those that may get exposed once the industry moves into a more traditional financial system.